Kemal Çavdarlı
Research Subjects
Research Interests
Kemal Çavdarlı has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Ozlem Turkoglu
Department of Radiology, Hamidiye Faculty of Medicine University of Health Sciences İstanbul Turkey
3 shared publications - Zafer Usta
Department of Genetics, Faculty of Veterinary Medicine, Burdur Mehmet Akif Ersoy University, Burdur, Turkey
3 shared publications - Adem Milletsever
Department of Pathology, Faculty of Veterinary Medicine, Burdur Mehmet Akif Ersoy University, Burdur, Turkey
1 shared publication - Harun Karaca
Department of Histology and Embryology, Faculty of Veterinary Medicine, Burdur Mehmet Akif Ersoy University, Burdur, Turkey
1 shared publication - Nur Alp
Süleyman Demirel Üniversitesi
1 shared publication - Sevilay Kılınçkaya
Department of Geriatric Care, Isparta Vocational School of Health Services, Süleyman Demirel University, Isparta, Turkey
1 shared publication
Latest Publications
- 21 April 2026
- Published by Elsevier in The Journal of Pharmacology and Experimental Therapeutics
- Vol. 393 (6) , 104893
Agomelatine restores apoptotic and glial homeostasis in methotrexate-induced cortical neurotoxicity
- 21 April 2026
- Published by Elsevier in The Journal of Pharmacology and Experimental Therapeutics
- Vol. 393 (6) , 104893
Agomelatine restores apoptotic and glial homeostasis in methotrexate-induced cortical neurotoxicity
- 15 February 2026
- Published by Wiley in Journal of Applied Toxicology
- Vol. 46 (9) , 3102-3112
L‐Carnitine Attenuates Methotrexate‐Induced Nephrotoxicity by Modulating BAX/BCL2 Apoptotic Signaling and Preserving Podocyte, Endothelial, and Tubular Integrity
Methotrexate (MTX), a common chemotherapeutic and immunosuppressive drug, is limited by dose‐dependent nephrotoxicity mediated by oxidative stress, mitochondrial dysfunction, and apoptosis. L‐carnitine (LCR), a mitochondrial cofactor with antioxidant and anti‐apoptotic properties, may counteract these mechanisms. This study aims to determine whether LCR mitigates MTX‐induced nephrotoxicity by rebalancing the BAX/BCL2 apoptotic axis and preserving renal compartment integrity (endothelial CD31, tubular cytokeratin, podocyte WT1). Twenty‐four female Wistar rats were randomized into Control, MTX (20 mg/kg, i.p., Day 5), LCR (200 mg/kg/day, i.p., 10 days), and MTX + LCR groups ( n = 6 each). Renal injury was assessed by serum creatinine, urea, BUN, histopathology, immunohistochemistry (CD31, cytokeratin, WT1), and RT‐qPCR for BAX/BCL2. MTX impaired renal function, caused vascular hyperemia, hemorrhage, and tubular necrosis, increased CD31, cytokeratin, and BAX and decreased WT1 and BCL2. LCR co‐treatment improved biochemical indices, reduced lesions, decreased CD31 and cytokeratin, partially restored WT1 and re‐balanced apoptosis (BAX↓, BCL2↑). LCR disrupts oxidative stress, the mitochondrial apoptosis cascade, and preserves endothelial, tubular, and podocyte integrity in MTX nephrotoxicity.
- 15 February 2026
- Published by Wiley in Journal of Applied Toxicology
- Vol. 46 (9) , 3102-3112
L‐Carnitine Attenuates Methotrexate‐Induced Nephrotoxicity by Modulating BAX/BCL2 Apoptotic Signaling and Preserving Podocyte, Endothelial, and Tubular Integrity
Methotrexate (MTX), a common chemotherapeutic and immunosuppressive drug, is limited by dose‐dependent nephrotoxicity mediated by oxidative stress, mitochondrial dysfunction, and apoptosis. L‐carnitine (LCR), a mitochondrial cofactor with antioxidant and anti‐apoptotic properties, may counteract these mechanisms. This study aims to determine whether LCR mitigates MTX‐induced nephrotoxicity by rebalancing the BAX/BCL2 apoptotic axis and preserving renal compartment integrity (endothelial CD31, tubular cytokeratin, podocyte WT1). Twenty‐four female Wistar rats were randomized into Control, MTX (20 mg/kg, i.p., Day 5), LCR (200 mg/kg/day, i.p., 10 days), and MTX + LCR groups ( n = 6 each). Renal injury was assessed by serum creatinine, urea, BUN, histopathology, immunohistochemistry (CD31, cytokeratin, WT1), and RT‐qPCR for BAX/BCL2. MTX impaired renal function, caused vascular hyperemia, hemorrhage, and tubular necrosis, increased CD31, cytokeratin, and BAX and decreased WT1 and BCL2. LCR co‐treatment improved biochemical indices, reduced lesions, decreased CD31 and cytokeratin, partially restored WT1 and re‐balanced apoptosis (BAX↓, BCL2↑). LCR disrupts oxidative stress, the mitochondrial apoptosis cascade, and preserves endothelial, tubular, and podocyte integrity in MTX nephrotoxicity.
- 29 October 2025
- Published by Wiley in Journal of Applied Toxicology
- Vol. 46 (5) , 1575-1582
L‐Carnitine Attenuates Methotrexate‐Induced Cortical Neurotoxicity via Glial and Apoptotic Pathways
Methotrexate (MTX) is a widely used chemotherapeutic and immunosuppressive agent, but its clinical application is limited by dose‐dependent neurotoxicity, particularly in the cerebral cortex. MTX‐induced injury involves oxidative imbalance, mitochondrial dysfunction, glial activation, and apoptosis. L‐carnitine (LCR), a mitochondrial cofactor with antioxidant and antiapoptotic properties, has been proposed as a potential neuroprotective agent. This study investigated whether LCR could attenuate MTX‐induced cortical damage in rats. Twenty‐four female Wistar rats were randomly assigned to four groups ( n = 6): control, MTX, LCR, and MTX + LCR. MTX (20 mg/kg, i.p.) was given on Day 5, whereas LCR (200 mg/kg, i.p.) was administered daily for 10 days. Cortical tissue was evaluated histopathologically, immunohistochemically for GFAP and OLIG2, and by qRT‐PCR for BAX and BCL2 expression. MTX caused severe cortical degeneration, perivascular edema, reactive astrogliosis, oligodendroglial activation, and a significant increase in the BAX/BCL2 ratio. LCR co‐treatment markedly reduced histological injury, attenuated glial activation, and restored apoptotic balance toward cell survival. LCR alone showed no adverse effects compared with controls. These findings demonstrate that LCR provides effective neuroprotection against MTX‐induced cortical injury in rats.
- 29 October 2025
- Published by Wiley in Journal of Applied Toxicology
- Vol. 46 (5) , 1575-1582
L‐Carnitine Attenuates Methotrexate‐Induced Cortical Neurotoxicity via Glial and Apoptotic Pathways
Methotrexate (MTX) is a widely used chemotherapeutic and immunosuppressive agent, but its clinical application is limited by dose‐dependent neurotoxicity, particularly in the cerebral cortex. MTX‐induced injury involves oxidative imbalance, mitochondrial dysfunction, glial activation, and apoptosis. L‐carnitine (LCR), a mitochondrial cofactor with antioxidant and antiapoptotic properties, has been proposed as a potential neuroprotective agent. This study investigated whether LCR could attenuate MTX‐induced cortical damage in rats. Twenty‐four female Wistar rats were randomly assigned to four groups ( n = 6): control, MTX, LCR, and MTX + LCR. MTX (20 mg/kg, i.p.) was given on Day 5, whereas LCR (200 mg/kg, i.p.) was administered daily for 10 days. Cortical tissue was evaluated histopathologically, immunohistochemically for GFAP and OLIG2, and by qRT‐PCR for BAX and BCL2 expression. MTX caused severe cortical degeneration, perivascular edema, reactive astrogliosis, oligodendroglial activation, and a significant increase in the BAX/BCL2 ratio. LCR co‐treatment markedly reduced histological injury, attenuated glial activation, and restored apoptotic balance toward cell survival. LCR alone showed no adverse effects compared with controls. These findings demonstrate that LCR provides effective neuroprotection against MTX‐induced cortical injury in rats.